A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
Solid Tumor
DRUG: BHV-1530
Dose-escalation and Dose-expansion Cohorts: Number of patients with AEs, Incidence and severity of treatment emergent adverse events (TEAEs), including dose-limiting toxicities (DLTs) and serious adverse events (SAEs), Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Recommended dose of BHV-1530 for later phase trials, Incidence and severity of adverse events (AEs) and SAEs, dose reductions during treatment, study discontinuation rates due to TEAEs, and signals of antitumor activity, Through study completion, estimated as an average of 48 months
Dose-escalation and Dose-expansion Cohorts: Clinical Benefit Rate (CBR), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Objective Response Rate (ORR), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Disease Control Rate (DCR), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Time to Response (TTR), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Duration of Response (DOR), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Progression-free Survival (PFS), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Maximum observed serum concentration (Cmax), Serum concentration of BHV-1530, total antibody and TopoIx BHV-0080269, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Time of maximum concentration (Tmax), Time of maximum concentration of BHV-1530, total antibody and TopoIx BHV-0080269, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Elimination half-life (t½), Terminal elimination half-life (t½) of BHV-1510, total antibody and TopoIx BHV-0080269, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Area Under the Concentration versus time curve (AUC), Area under the concentration-time curve from zero to last quantifiable concentration (AUC0-t) and AUC extrapolated to infinity (AUC0-inf) and AUC over the dosing interval (AUCtau), Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Trough concentration (Ctrough), Trough concentration of BHV-1530, total antibody and TopoIx BHV-0080269, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Total body clearance (CL), Total body clearance of BHV-1530 and total antibody, Through study completion, estimated as an average of 48 months|Dose-escalation and Dose-expansion Cohorts: Volume of distribution at steady state (Vss), Volume of distribution of BHV-1530 and total antibody, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Objective Response Rate (ORR), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Disease Control Rate (DCR), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Time to Response (TTR), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Duration of Response (DOR), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Progression-free Survival (PFS), Assessed by RECIST v 1.1, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Maximum observed serum concentration (Cmax), Serum concentration of BHV-1530, total antibody and free payload TopoIx BHV-0080269, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Time of maximum concentration (Tmax), Time of maximum concentration of BHV-1530, total antibody and TopoIx BHV-0080269, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Elimination half-life (t½) of BHV-1530, Terminal elimination half-life (t½) of BHV-1510, total antibody and TopoIx BHV-0080269, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Area Under the Concentration versus time curve (AUC), Area under the concentration-time curve from zero to last quantifiable concentration (AUC0-t) and AUC extrapolated to infinity (AUC0-inf) and AUC over the dosing interval (AUCtau), Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Trough concentration (Ctrough), Trough concentration of BHV-1530, total antibody and TopoIx BHV-0080269, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Total body clearance (CL), Total body clearance of BHV-1530 and total antibody, Through study completion, estimated as an average of 48 months|Dose-confirmation Cohorts: Volume of distribution at steady state (Vss), Volume of distribution of BHV-1530 and total antibody, Through study completion, estimated as an average of 48 months
This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.